Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a

Takashi Kurizaki, Shinji Okazaki, Sam D. Sanderson, David Colcher, Charles Arthur Enke, Margaret A. Tempero, Janina Baranowska-Kortylewicz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Physiologic barriers to the delivery of macromolecules to solid tumors are a major obstacle to the clinical success of radioimmunotherapy (RIT). Only a small fraction of the injected dose of the radiolabeled monoclonal antibody (mAb) localizes at the tumor site. This situation worsens as the tumor burden increases. It is hypothesized that improvements to RIT of adenocarcinoma can be realized by inclusion of vasoactive agents, in particular agents able to increase the vascular permeability of tumor capillaries. In these studies, a response-selective peptide agonist of human C5a, GCGYSFKPMPLaR (AP), was used to transiently increase tumor vascular permeability in an effort to improve RIT of solid tumors. Methods: Athymic mice xenografted with human colorectal adenocarcinoma LS174T were treated intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intravenous doses of AP. The progression of the disease or the loss of >20% body weight was taken as the endpoint. Biodistribution and tumor uptake kinetics were studied in the same tumor-antibody system. Results: The uptake of 125I-B72.3 in LS174T xenografts increased in a dose-dependent manner with an apparent maximal effect between 3 and 6 h after intravenous administration of AP. Augmenting the dose of 9.25 MBq 131I-B72.3 with a single administration of 0.1 mg AP delayed tumor growth nearly 2-fold; the tumor quadrupling time (Tq) was 14.2 ± 3.3 d for 131I-B72.3 alone versus 26.0 ± 3.6 d for 131I-B72.3 plus 0.1 mg AP (P < 0.001). An additional dose of 0.1 mg AP 24 h after 131I-B72.3 further improved the therapeutic outcome (Tq = 48.5 ± 7.9 d; P < 0.001) and resulted in several cases of tumor regression. Conclusion: The inclusion of agonist peptides of human C5a in the RIT scheme results in improved tumor responses without any manifest side effects.

Original languageEnglish (US)
Pages (from-to)957-967
Number of pages11
JournalJournal of Nuclear Medicine
Volume43
Issue number7
StatePublished - Jul 20 2002

Fingerprint

Radioimmunotherapy
Peptides
Neoplasms
Capillary Permeability
Adenocarcinoma
Monoclonal Antibodies
Neoplasm Antibodies
Tumor Burden
Heterografts
Nude Mice
Intravenous Administration
Disease Progression
B72.3 antibody

Keywords

  • Adenocarcinoma
  • C5a agonist
  • Radioimmunotherapy
  • Tumor uptake
  • Vascular permeability

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. / Kurizaki, Takashi; Okazaki, Shinji; Sanderson, Sam D.; Colcher, David; Enke, Charles Arthur; Tempero, Margaret A.; Baranowska-Kortylewicz, Janina.

In: Journal of Nuclear Medicine, Vol. 43, No. 7, 20.07.2002, p. 957-967.

Research output: Contribution to journalArticle

Kurizaki, T, Okazaki, S, Sanderson, SD, Colcher, D, Enke, CA, Tempero, MA & Baranowska-Kortylewicz, J 2002, 'Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a', Journal of Nuclear Medicine, vol. 43, no. 7, pp. 957-967.
Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA et al. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. Journal of Nuclear Medicine. 2002 Jul 20;43(7):957-967.
Kurizaki, Takashi ; Okazaki, Shinji ; Sanderson, Sam D. ; Colcher, David ; Enke, Charles Arthur ; Tempero, Margaret A. ; Baranowska-Kortylewicz, Janina. / Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. In: Journal of Nuclear Medicine. 2002 ; Vol. 43, No. 7. pp. 957-967.
@article{b5ecabfb6d864eed96a0fd989cbb2e19,
title = "Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a",
abstract = "Physiologic barriers to the delivery of macromolecules to solid tumors are a major obstacle to the clinical success of radioimmunotherapy (RIT). Only a small fraction of the injected dose of the radiolabeled monoclonal antibody (mAb) localizes at the tumor site. This situation worsens as the tumor burden increases. It is hypothesized that improvements to RIT of adenocarcinoma can be realized by inclusion of vasoactive agents, in particular agents able to increase the vascular permeability of tumor capillaries. In these studies, a response-selective peptide agonist of human C5a, GCGYSFKPMPLaR (AP), was used to transiently increase tumor vascular permeability in an effort to improve RIT of solid tumors. Methods: Athymic mice xenografted with human colorectal adenocarcinoma LS174T were treated intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intravenous doses of AP. The progression of the disease or the loss of >20{\%} body weight was taken as the endpoint. Biodistribution and tumor uptake kinetics were studied in the same tumor-antibody system. Results: The uptake of 125I-B72.3 in LS174T xenografts increased in a dose-dependent manner with an apparent maximal effect between 3 and 6 h after intravenous administration of AP. Augmenting the dose of 9.25 MBq 131I-B72.3 with a single administration of 0.1 mg AP delayed tumor growth nearly 2-fold; the tumor quadrupling time (Tq) was 14.2 ± 3.3 d for 131I-B72.3 alone versus 26.0 ± 3.6 d for 131I-B72.3 plus 0.1 mg AP (P < 0.001). An additional dose of 0.1 mg AP 24 h after 131I-B72.3 further improved the therapeutic outcome (Tq = 48.5 ± 7.9 d; P < 0.001) and resulted in several cases of tumor regression. Conclusion: The inclusion of agonist peptides of human C5a in the RIT scheme results in improved tumor responses without any manifest side effects.",
keywords = "Adenocarcinoma, C5a agonist, Radioimmunotherapy, Tumor uptake, Vascular permeability",
author = "Takashi Kurizaki and Shinji Okazaki and Sanderson, {Sam D.} and David Colcher and Enke, {Charles Arthur} and Tempero, {Margaret A.} and Janina Baranowska-Kortylewicz",
year = "2002",
month = "7",
day = "20",
language = "English (US)",
volume = "43",
pages = "957--967",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a

AU - Kurizaki, Takashi

AU - Okazaki, Shinji

AU - Sanderson, Sam D.

AU - Colcher, David

AU - Enke, Charles Arthur

AU - Tempero, Margaret A.

AU - Baranowska-Kortylewicz, Janina

PY - 2002/7/20

Y1 - 2002/7/20

N2 - Physiologic barriers to the delivery of macromolecules to solid tumors are a major obstacle to the clinical success of radioimmunotherapy (RIT). Only a small fraction of the injected dose of the radiolabeled monoclonal antibody (mAb) localizes at the tumor site. This situation worsens as the tumor burden increases. It is hypothesized that improvements to RIT of adenocarcinoma can be realized by inclusion of vasoactive agents, in particular agents able to increase the vascular permeability of tumor capillaries. In these studies, a response-selective peptide agonist of human C5a, GCGYSFKPMPLaR (AP), was used to transiently increase tumor vascular permeability in an effort to improve RIT of solid tumors. Methods: Athymic mice xenografted with human colorectal adenocarcinoma LS174T were treated intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intravenous doses of AP. The progression of the disease or the loss of >20% body weight was taken as the endpoint. Biodistribution and tumor uptake kinetics were studied in the same tumor-antibody system. Results: The uptake of 125I-B72.3 in LS174T xenografts increased in a dose-dependent manner with an apparent maximal effect between 3 and 6 h after intravenous administration of AP. Augmenting the dose of 9.25 MBq 131I-B72.3 with a single administration of 0.1 mg AP delayed tumor growth nearly 2-fold; the tumor quadrupling time (Tq) was 14.2 ± 3.3 d for 131I-B72.3 alone versus 26.0 ± 3.6 d for 131I-B72.3 plus 0.1 mg AP (P < 0.001). An additional dose of 0.1 mg AP 24 h after 131I-B72.3 further improved the therapeutic outcome (Tq = 48.5 ± 7.9 d; P < 0.001) and resulted in several cases of tumor regression. Conclusion: The inclusion of agonist peptides of human C5a in the RIT scheme results in improved tumor responses without any manifest side effects.

AB - Physiologic barriers to the delivery of macromolecules to solid tumors are a major obstacle to the clinical success of radioimmunotherapy (RIT). Only a small fraction of the injected dose of the radiolabeled monoclonal antibody (mAb) localizes at the tumor site. This situation worsens as the tumor burden increases. It is hypothesized that improvements to RIT of adenocarcinoma can be realized by inclusion of vasoactive agents, in particular agents able to increase the vascular permeability of tumor capillaries. In these studies, a response-selective peptide agonist of human C5a, GCGYSFKPMPLaR (AP), was used to transiently increase tumor vascular permeability in an effort to improve RIT of solid tumors. Methods: Athymic mice xenografted with human colorectal adenocarcinoma LS174T were treated intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intravenous doses of AP. The progression of the disease or the loss of >20% body weight was taken as the endpoint. Biodistribution and tumor uptake kinetics were studied in the same tumor-antibody system. Results: The uptake of 125I-B72.3 in LS174T xenografts increased in a dose-dependent manner with an apparent maximal effect between 3 and 6 h after intravenous administration of AP. Augmenting the dose of 9.25 MBq 131I-B72.3 with a single administration of 0.1 mg AP delayed tumor growth nearly 2-fold; the tumor quadrupling time (Tq) was 14.2 ± 3.3 d for 131I-B72.3 alone versus 26.0 ± 3.6 d for 131I-B72.3 plus 0.1 mg AP (P < 0.001). An additional dose of 0.1 mg AP 24 h after 131I-B72.3 further improved the therapeutic outcome (Tq = 48.5 ± 7.9 d; P < 0.001) and resulted in several cases of tumor regression. Conclusion: The inclusion of agonist peptides of human C5a in the RIT scheme results in improved tumor responses without any manifest side effects.

KW - Adenocarcinoma

KW - C5a agonist

KW - Radioimmunotherapy

KW - Tumor uptake

KW - Vascular permeability

UR - http://www.scopus.com/inward/record.url?scp=0036301413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036301413&partnerID=8YFLogxK

M3 - Article

C2 - 12097469

AN - SCOPUS:0036301413

VL - 43

SP - 957

EP - 967

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -